The World Health Organisation warns that a baby who is not vaccinated may survive childhood but still die of hepatitis B when he or she grows up.

“No infant should grow up only to die of hepatitis B because they were not vaccinated,” Director-General of WHO, Dr. Tedros Adhanom Ghebreyesus, says in a Press release ahead of this year’s World Hepatitis Day, which comes up on Tuesday, July 28.

Ghebreyesus noted that the proportion of children under five years of age chronically infected with hepatitis B dropped to just under one per cent in 2019 down from around five per cent in the pre-vaccine era.

That was the period between the 1980s and the early 2000s, according to new estimates from the WHO.

“This marks the achievement of one of the milestone targets to eliminate viral hepatitis in the Sustainable Development Goals ─ to reach under one per cent prevalence of HBV infections in children under five years of age by 2020,” the Press release stated.

Underscoring the importance of vaccination as a preventive measure against hepatitis B, Ghebreyesus said:

“No infant should grow up only to die of hepatitis B because they were not vaccinated ─ today’s milestone means that we have dramatically reduced the number of cases of liver damage and liver cancer in future generations.”

Enumerating the preventive strategies, he said, “Preventing mother-to-child transmission of hepatitis B is the most important strategy for controlling the disease and saving lives.

“Even in the midst of the COVID-19 pandemic, we must ensure that mothers and newborns have access to life-saving services, including hepatitis B vaccinations.”

On World Hepatitis Day 2020, WHO is calling for united and stepped-up action to build on this achievement through intensified efforts to prevent mother-to-child transmission of hepatitis B virus, HBV, through testing pregnant women and provision of antiviral prophylaxis to those who need it and maintaining and expanding access to hepatitis B immunisation and birth dose vaccine.

Stating the global prevalence of the communicable disease, Ghebreyesus said, “Globally, more than 250 million people are living with chronic HBV infection. Infants are especially vulnerable: about 90 per cent of children infected with HBV in their first year of life become chronic HBV carriers. HBV attacks the liver and claims the lives of nearly 900,000 people each year.”

Preventing hepatitis B
Infants can be protected from HBV through a safe and effective vaccine that provides over 95 per cent protection against infection.

WHO recommends that all infants receive a first dose of the hepatitis B vaccine as soon as possible after birth – preferably within 24 hours – followed by at least two additional doses.

“The scale-up of hepatitis B vaccine worldwide over the last two decades, which has been in large part due to the support provided by Gavi, the Vaccine Alliance, has been a great public health success story and contributed to the decrease in HBV infections among children.

In 2019, coverage of three doses of the hepatitis B vaccine during childhood reached 85% worldwide, up from around 30 per cent in 2000. However, access to the first critical dose within 24 hours of birth remains uneven.

“Global coverage of this birth dose is 43 per cent, but this drops to 34 per cent in the WHO Eastern Mediterranean Region and only six per cent in the WHO African Region.

“Expanding access to a timely birth dose of the hepatitis B vaccine is the cornerstone of efforts to prevent mother-to-children transmission of HBV.

“For countries especially in regions such as sub-Saharan Africa, where the birth dose of hepatitis B vaccine has not yet been introduced, it is a priority to assure that protection as early as possible,” said the Director of Global HIV, Hepatitis and STI Programmes, Dr Meg Doherty.

An additional way to protect children is to provide pregnant women with antiviral treatment to reduce mother-to-child transmission of HBV.

WHO already recommends routine testing of all pregnant women for HBV, as well as HIV and syphilis as early as possible in their pregnancy. In view of new evidence on the safety and efficacy of antiviral prophylaxis in pregnant women and their children, WHO is issuing today two new recommendations:

Pregnant women who test positive for hepatitis B infection and have a high level of HBV in the blood (known as HBV viral load) should receive preventive antiviral therapy with tenofovir from the 28th week of pregnancy until birth.

The antiviral drug, tenofovir is available at low cost in many countries of the world for less than $3 per month.

In settings where HBV viral load testing is not available, WHO recommends the use of an alternative low cost test (HBeAg) to determine whether a woman is eligible for preventive antiviral therapy.

In countries that have already achieved high coverage of hepatitis B immunization, including timely birth dose, routine testing for HBV infection among pregnant women and antiviral prophylaxis for those in need is an additional opportunity to prevent onward transmission from mother to child.

“Stopping vertical transmission of HBV is a key pillar of the global ‘triple elimination’ initiative, which seeks to eliminate mother-to-child transmission of three infections that are prevalent in low- and middle-income countries: HIV, syphilis and hepatitis B virus,” added Dr Doherty.

Eliminating mother-to-child transmission of HBV is also an important stepping stone for reaching the targets of WHO’s global hepatitis strategy, which aims to reduce new hepatitis infections by 90% and deaths by 65%, compared to 2015 levels.

The COVID-19 pandemic jeopardizes future progress
COVID-19 threatens to hamper progress in eliminating HBV. According to a new modelling study conducted by Imperial College London in collaboration with WHO, disruptions to the hepatitis B vaccination programme due to the pandemic could have a serious impact on efforts to reach the targets of the global strategy.

Under a worst-case scenario, with high levels of disruptions of both the birth dose and childhood HBV immunization (by 60% and 20% for one year respectively), as well as a delay and slow recovery in the expansion of the vaccination programme towards the planned 2030 WHO-targets in the post-COVID-19 period, there would be a projected 5.3 million additional chronic HBV infections among children born between 2020 and 2030 and 1 million additional HBV-related deaths among those children later on. Thus, missed opportunities now to prevent new HBV infections will have a long-lasting and life-impacting effect.